A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).

被引：0
|
作者：
Guo, Changying
Chen, Shengjia
Ye, Yongqiang
Mao, Wei-Min
机构：
[1] Jiangxi Prov Tumor Hosp, Nanchang, Jiangxi, Peoples R China
[2] Jiujiang 1 Peoples Hosp, Jiujiang, Peoples R China
[3] Ganzhou Canc Hosp, Ganzhou, Peoples R China
[4] Zhejing Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS488
引用
收藏
页码：TPS488 / TPS488
页数：1
相关论文
共 50 条
  • [31] Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study
    Zhao, Jinbo
    Yan, Xiaolong
    Bai, Yuquan
    Duan, Hongtao
    Jiang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] A multicenter phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
    Kim, J.
    Song, H.
    Do, Y.
    Kim, M.
    Lee, K.
    Bae, S.
    Ryoo, H.
    Park, K.
    Baek, J.
    Lee, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
    Yun, Tak
    Han, Ji-Youn
    Lee, Jin Soo
    Choi, Hyun Lee
    Kim, Hyae Young
    Nam, Byung-Ho
    Kim, Heung Tae
    BMC CANCER, 2011, 11
  • [34] Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.
    Rojas, Carlos
    Ryoo, Baek-Yeol
    Rha, Sun Young
    Kelley, Robin Kate
    Hubert, Ayala
    Painemal, Claudio
    Wadlow, Raymond Couric
    Gong, Jun
    Fan, Li
    Jin, Fan
    Naik, Girish S.
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS425 - TPS425
  • [35] Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
    Tak Yun
    Ji-Youn Han
    Jin Soo Lee
    Hyun Lee Choi
    Hyae Young Kim
    Byung-Ho Nam
    Heung Tae Kim
    BMC Cancer, 11
  • [36] Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)
    Sheng, X.
    Shen, P.
    Qu, W.
    Wang, Z.
    Li, Y.
    Ren, X.
    Jiang, S.
    Li, G.
    Fu, C.
    Qin, W.
    Wu, J.
    Chen, P.
    Guo, H.
    Zhou, F.
    Ji, Z.
    Yang, A.
    Chen, K.
    Li, L.
    Zhou, A.
    Guo, J.
    ANNALS OF ONCOLOGY, 2024, 35 : 1263 - 1264
  • [37] A phase II study to evaluate safety and efficacy of PD-1 blockade plus anti-EGFR target therapy plus chemotherapy in patients with advanced penile squamous cell carcinoma
    Shi, Y.
    An, X.
    Yan, R.
    Yao, K.
    Xue, C.
    Guo, S.
    Liu, T.
    Li, J.
    Ma, H.
    Tian, L.
    Zhou, F.
    Shi, Y.
    Han, H.
    EUROPEAN UROLOGY, 2021, 79 : S933 - S933
  • [38] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [39] Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma
    Liu, Qi
    Zhu, Zhengfei
    Chen, Yun
    Deng, Jiaying
    Ai, Dashan
    Liu, Quan
    Wang, Shengping
    Wu, Shixiu
    Chen, Junqiang
    Zhao, Kuaile
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : 707 - 715
  • [40] A phase II study cohort of penpulimab plus anlotinib in patients with recurrent or metastatic non-squamous cell carcinomas of head and neck
    Zhang, Changgong
    Sun, Yan
    Wang, Jun
    Liu, Zhigang
    Su, Haichuan
    Chen, Jianhua
    Tian, Youxin
    Wu, Huijuan
    Gao, Liying
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345